Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
Results Follow ACTIVATE Study Data In December
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
You may also be interested in...
Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.
Nine Major Approval Decisions To Watch In Early 2022
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
Atavistik Bio Raises $60m For Metabolic Disease, Cancer Drug Discovery
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.